Suppression of endothelial cell FAK expression reduces pancreatic ductal adenocarcinoma metastasis after gemcitabine treatment
M Roy-Luzarraga, LE Reynolds, B de Luxán-Delgado… - Cancer Research, 2022 - AACR
Despite substantial advances in the treatment of solid cancers, resistance to therapy
remains a major obstacle to prolonged progression-free survival. Pancreatic ductal …
remains a major obstacle to prolonged progression-free survival. Pancreatic ductal …
FAK activity in cancer‐associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer
S Zaghdoudi, E Decaup, I Belhabib… - EMBO molecular …, 2020 - embopress.org
Cancer‐associated fibroblasts (CAF s) are considered the most abundant type of stromal
cells in pancreatic ductal adenocarcinoma (PDAC), playing a critical role in tumour …
cells in pancreatic ductal adenocarcinoma (PDAC), playing a critical role in tumour …
Molecular pathways: endothelial cell FAK—a target for cancer treatment
M Roy-Luzarraga, K Hodivala-Dilke - Clinical Cancer Research, 2016 - AACR
The nonreceptor protein tyrosine kinase, focal adhesion kinase (FAK, also known as PTK2),
is a key mediator of signal transduction downstream of integrins and growth factor receptors …
is a key mediator of signal transduction downstream of integrins and growth factor receptors …
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma
A Begum, T Ewachiw, C Jung, A Huang, KJ Norberg… - PloS one, 2017 - journals.plos.org
Cancer stem cells (CSCs) play an important role in the clonogenic growth and metastasis of
pancreatic ductal adenocarcinoma (PDAC). A hallmark of PDAC is the desmoplastic …
pancreatic ductal adenocarcinoma (PDAC). A hallmark of PDAC is the desmoplastic …
Elucidating the role of the kinase activity of endothelial cell focal adhesion kinase in angiocrine signalling and tumour growth
E Newport, AR Pedrosa, D Lees… - The Journal of …, 2022 - Wiley Online Library
A common limitation of cancer treatments is chemotherapy resistance. We have previously
identified that endothelial cell (EC)‐specific deletion of focal adhesion kinase (FAK) …
identified that endothelial cell (EC)‐specific deletion of focal adhesion kinase (FAK) …
[HTML][HTML] The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth
E Kurenova, J Liao, DH He, D Hunt, M Yemma… - Oncotarget, 2013 - ncbi.nlm.nih.gov
Even with successful surgical resection and perioperative chemotherapy and radiation,
pancreatic ductal adenocarcinoma (PDA) has a high incidence of recurrence. Tumor cell …
pancreatic ductal adenocarcinoma (PDA) has a high incidence of recurrence. Tumor cell …
[HTML][HTML] Inhibition of FAK kinase activity preferentially targets cancer stem cells
VN Kolev, WF Tam, QG Wright, SP McDermott… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Because cancer stem cells (CSCs) have been implicated in chemo-resistance, metastasis
and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical …
and tumor recurrence, therapeutic targeting of CSCs holds promise to address these clinical …
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment
JB Stokes, SJ Adair, JK Slack-Davis, DM Walters… - Molecular cancer …, 2011 - AACR
Current therapies for pancreatic ductal adenocarcinoma (PDA) target individual tumor cells.
Focal adhesion kinase (FAK) is activated in PDA, and levels are inversely associated with …
Focal adhesion kinase (FAK) is activated in PDA, and levels are inversely associated with …
Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma
TYS Le Large, MF Bijlsma, B El Hassouni… - Journal of Experimental …, 2021 - Springer
Background Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease, with
minimal therapeutic options. Aberrant tyrosine kinase activity influences tumor growth and is …
minimal therapeutic options. Aberrant tyrosine kinase activity influences tumor growth and is …
A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells
J Zhang, DH He, M Zajac-Kaye, SN Hochwald - Cell cycle, 2014 - Taylor & Francis
Focal adhesion kinase (FAK) hyperactivation is common in pancreatic ductal
adenocarcinoma (PDAC). A small molecule, GSK2256098 (GlaxoSmithKline), has been …
adenocarcinoma (PDAC). A small molecule, GSK2256098 (GlaxoSmithKline), has been …